GLIS1

Summary

GLIS1 (GLIS family zinc finger 1, HGNC:29525) is a protein-coding gene on chromosome 1p32.3, encoding Zinc finger protein GLIS1 (Q8NBF1). Acts both as a repressor and an activator of transcription.

GLIS1 is a GLI (MIM 165220)-related Kruppel-like zinc finger protein that functions as an activator and repressor of transcription (Kim et al., 2002 [PubMed 12042312]).

Source: NCBI Gene 148979 — RefSeq curated summary.

At a glance

• Gene–disease (curated): glaucoma (Limited, GenCC)
• GWAS associations: 16
• Clinical variants (ClinVar): 131 total
• MANE Select transcript: NM_001367484

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29525
Approved symbol	GLIS1
Name	GLIS family zinc finger 1
Location	1p32.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ36155
Ensembl gene	ENSG00000174332
Ensembl biotype	protein_coding
OMIM	610378
Entrez	148979

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000312233, ENST00000628545, ENST00000863985, ENST00000954872

RefSeq mRNA: 5 — MANE Select: NM_001367484 NM_001367484, NM_001390836, NM_001390837, NM_001390838, NM_147193

CCDS: CCDS582, CCDS90959

Canonical transcript exons

ENST00000628545 — 11 exons

Exon	Start	End
ENSE00001190051	53509120	53509287
ENSE00001190058	53509849	53510027
ENSE00001190061	53514625	53514781
ENSE00001190065	53520634	53520766
ENSE00001190082	53529791	53529952
ENSE00001626089	53524777	53524887
ENSE00003768595	53506239	53506776
ENSE00003769919	53594108	53594990
ENSE00003773046	53600101	53600278
ENSE00003774329	53737806	53738106
ENSE00003931491	53739105	53739164

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 78.32.

FANTOM5 (CAGE): breadth broad, TPM avg 2.4427 / max 109.7466, expressed in 546 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
12423	1.8867	498
12421	0.2249	91
12424	0.1730	78
12422	0.1204	69
12417	0.0377	15

Top tissues by expression

229 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	78.32	gold quality
seminal vesicle	UBERON:0000998	77.13	gold quality
prostate gland	UBERON:0002367	72.44	gold quality
endocervix	UBERON:0000458	71.08	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	70.62	gold quality
primary visual cortex	UBERON:0002436	69.86	gold quality
right hemisphere of cerebellum	UBERON:0014890	69.28	gold quality
pigmented layer of retina	UBERON:0001782	68.17	gold quality
cerebellar hemisphere	UBERON:0002245	67.90	gold quality
cerebellar cortex	UBERON:0002129	67.85	gold quality
ectocervix	UBERON:0012249	67.83	gold quality
mucosa of stomach	UBERON:0001199	67.75	gold quality
cerebellum	UBERON:0002037	66.73	gold quality
adult mammalian kidney	UBERON:0000082	66.38	gold quality
vagina	UBERON:0000996	66.29	gold quality
urethra	UBERON:0000057	66.14	silver quality
right coronary artery	UBERON:0001625	65.09	gold quality
right frontal lobe	UBERON:0002810	64.56	gold quality
cauda epididymis	UBERON:0004360	64.33	silver quality
uterine cervix	UBERON:0000002	64.23	gold quality
skin of leg	UBERON:0001511	64.02	gold quality
kidney	UBERON:0002113	63.63	gold quality
tibial artery	UBERON:0007610	63.13	gold quality
popliteal artery	UBERON:0002250	63.12	gold quality
urinary bladder	UBERON:0001255	62.61	gold quality
amniotic fluid	UBERON:0000173	62.57	gold quality
zone of skin	UBERON:0000014	62.42	gold quality
cortex of kidney	UBERON:0001225	62.41	gold quality
occipital lobe	UBERON:0002021	62.35	gold quality
penis	UBERON:0000989	61.94	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.92

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
WNT5A	Activation

JASPAR motifs

Motif	Name	Family
MA0735.1	GLIS1	More than 3 adjacent zinc fingers
MA0735.2	GLIS1	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:22391303

Upstream regulators (CollecTRI, top): GLI1

miRNA regulators (miRDB)

41 targeting GLIS1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-4679	99.76	69.19	1229
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-6766-5P	99.68	67.70	2325
HSA-MIR-4328	99.57	71.06	4094
HSA-MIR-17-3P	99.55	66.77	1311
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4677-3P	99.49	67.91	1246
HSA-MIR-578	99.46	68.36	1787

Literature-anchored findings (GeneRIF, showing 10)

• Transcriptional factor Glis1 is involved in the regulation of aberrant differentiation observed in psoriatic epidermis. (PMID:16417217)
• results therefore show that Glis1 effectively promotes the direct reprogramming of somatic cells during iPSC generation. (PMID:21654807)
• found that allele ‘A’ of rs797906 SNP increases the risk for late-onset Parkinson Disease in the Han Chinese population. (PMID:22759478)
• These results suggest that the hypoxic signaling pathway may play a pivotal role in regulating the reprogramming factor GLIS1, via non-canonical mechanisms involving partner transcription factor rather than by direct HIF transactivation. (PMID:24383088)
• GLIS1 is a susceptibility gene for mitral valve prolapse. (PMID:31112420)
• GLIS1, a novel hypoxia-inducible transcription factor, promotes breast cancer cell motility via activation of WNT5A. (PMID:32047936)
• Gene of the month: GLIS1-3. (PMID:32699115)
• Elevating microRNA-1-3p shuttled by cancer-associated fibroblasts-derived extracellular vesicles suppresses breast cancer progression and metastasis by inhibiting GLIS1. (PMID:33154575)
• GLIS1 in Cancer-Associated Fibroblasts Regulates the Migration and Invasion of Ovarian Cancer Cells. (PMID:35216340)
• Effect of GLIS1 on the Lymph Node Metastasis of Cervical Squamous Carcinoma Based on Transcriptome Analysis. (PMID:38157104)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	glis1b	ENSDARG00000027933
mus_musculus	Glis1	ENSMUSG00000034762
rattus_norvegicus	Glis1	ENSRNOG00000000138

Paralogs (14): ZIC2 (ENSG00000043355), ZXDC (ENSG00000070476), GLI2 (ENSG00000074047), GLI3 (ENSG00000106571), GLIS3 (ENSG00000107249), GLI1 (ENSG00000111087), GLIS2 (ENSG00000126603), AEBP2 (ENSG00000139154), ZIC5 (ENSG00000139800), ZIC1 (ENSG00000152977), ZIC3 (ENSG00000156925), ZIC4 (ENSG00000174963), ZXDA (ENSG00000198205), ZXDB (ENSG00000198455)

Protein

Protein identifiers

Zinc finger protein GLIS1 — Q8NBF1 (reviewed: Q8NBF1)

Alternative names: GLI-similar 1

All UniProt accessions (2): Q8NBF1, A0A0D9SEX9

UniProt curated annotations — full annotation on UniProt →

Function. Acts both as a repressor and an activator of transcription. Binds to the consensus sequence 5’-GACCACCCAC-3’. By controlling the expression of genes involved in cell differentiation inhibits the lineage commitment of multipotent cells. Prevents, for instance, the differentiation of multipotent mesenchymal cells into adipocyte and osteoblast.

Subunit / interactions. Interacts with KLF4. Interacts with POU5F1 and/or POU5F1B. Interacts with SOX2.

Subcellular location. Nucleus.

Similarity. Belongs to the GLI C2H2-type zinc-finger protein family.

RefSeq proteins (5): NP_001354413, NP_001377765, NP_001377766, NP_001377767, NP_671726 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR043359	GLI-like	Family
IPR056436	Znf-C2H2_ZIC1-5/GLI1-3-like	Domain

Pfam: PF00096, PF23561

UniProt features (15 total): zinc finger region 5, sequence variant 3, compositionally biased region 2, region of interest 2, chain 1, sequence conflict 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NBF1-F1	53.95	0.01

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 69 (showing top): AACTGGA_MIR145, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOCC_NUCLEAR_BODY, GSE13762_CTRL_VS_125_VITAMIND_DAY12_DC_UP, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, LIU_PROSTATE_CANCER_DN, MEISSNER_BRAIN_HCP_WITH_H3K4ME3_AND_H3K27ME3, GOBP_NEGATIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_TRANSCRIPTION_BY_RNA_POLYMERASE_II, GOMF_DNA_BINDING_TRANSCRIPTION_ACTIVATOR_ACTIVITY, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, OVOL3_TARGET_GENES, SUPT16H_TARGET_GENES

GO Biological Process (8): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of transcription by RNA polymerase II (GO:0006357), cell differentiation (GO:0030154), positive regulation of transcription by RNA polymerase II (GO:0045944), osteoblast differentiation (GO:0001649), negative regulation of cell fate commitment (GO:0010454), fat cell differentiation (GO:0045444), positive regulation of DNA-templated transcription (GO:0045893)

GO Molecular Function (10): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), zinc ion binding (GO:0008270), sequence-specific double-stranded DNA binding (GO:1990837), RNA polymerase II transcription regulatory region sequence-specific DNA binding (GO:0000977), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	4
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	3
regulation of DNA-templated transcription	2
cell differentiation	2
DNA-binding transcription factor activity, RNA polymerase II-specific	2
negative regulation of DNA-templated transcription	1
cellular developmental process	1
positive regulation of DNA-templated transcription	1
ossification	1
regulation of cell fate commitment	1
cell fate commitment	1
negative regulation of cell differentiation	1
DNA-templated transcription	1
positive regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
transcription cis-regulatory region binding	1
negative regulation of transcription by RNA polymerase II	1
DNA-binding transcription repressor activity	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

996 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GLIS1	SPRR1B	P22528	726
GLIS1	KLK7	P49862	681
GLIS1	MYCL	P12524	678
GLIS1	NANOG	Q9H9S0	658
GLIS1	KLK6	Q92876	614
GLIS1	KDM2B	Q8NHM5	575
GLIS1	POU5F1	P31359	563
GLIS1	IVL	P07476	547
GLIS1	CAMK4	Q16566	545
GLIS1	TGM1	P22735	533
GLIS1	LIN28A	Q9H9Z2	528
GLIS1	SOX2	P48431	527
GLIS1	KLF4	P78338	523
GLIS1	MAP2K6	P52564	504
GLIS1	SALL4	Q9UJQ4	487

IntAct

21 interactions, top by confidence:

A	B	Type	Score
SPRR1A	GLIS1	psi-mi:“MI:0915”(physical association)	0.560
ZDHHC23	GLIS1	psi-mi:“MI:0915”(physical association)	0.560
BMI1	HMGB1P1	psi-mi:“MI:0914”(association)	0.350
BMI1	MEIS3P1	psi-mi:“MI:0914”(association)	0.350
GLIS1	AKT1	psi-mi:“MI:2364”(proximity)	0.270
SMAD4	GLIS1	psi-mi:“MI:2364”(proximity)	0.270
GLIS1	SMARCA4	psi-mi:“MI:2364”(proximity)	0.270
SMARCA4	GLIS1	psi-mi:“MI:2364”(proximity)	0.270
GLIS1	SPOP	psi-mi:“MI:2364”(proximity)	0.270
SPOP	GLIS1	psi-mi:“MI:2364”(proximity)	0.270
GLIS1	EGFR	psi-mi:“MI:2364”(proximity)	0.270
GLIS1	PTPN11	psi-mi:“MI:2364”(proximity)	0.270
GLIS1	SPRR1A	psi-mi:“MI:0915”(physical association)	0.000
GLIS1	ZDHHC23	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): GLIS1 (Affinity Capture-RNA), GLIS1 (FRET), SOX3 (FRET), TCF3 (FRET), ARNT (FRET), CDK6 (FRET), CDKN2A (FRET), LATS2 (FRET), MYC (FRET), RELA (FRET), TEAD2 (FRET), GLIS1 (FRET), GLIS1 (FRET), GLIS1 (Two-hybrid), ZDHHC23 (Two-hybrid)

ESM2 similar proteins: A1YF15, A2A5K6, A2A884, A2D4Z7, A5A763, F1QQA8, G3V893, O15062, O15090, O55170, P08151, P47806, P55198, P55878, P56693, Q00900, Q04888, Q3UHF7, Q5T1R4, Q62255, Q6DBW0, Q6XP49, Q6ZPI3, Q76IQ7, Q7TQG0, Q801E0, Q86V15, Q8BG87, Q8BX22, Q8IVH2, Q8K083, Q8NBF1, Q8R4Z4, Q91907, Q92766, Q96JN0, Q99LI5, Q99PV8, Q9C0K0, Q9CWL2

Diamond homologs: A0A5K4F1D0, A0JC51, A4FV57, O57311, O60481, O73689, O95409, P08151, P10070, P10071, P19538, P34708, P39768, P46684, P47806, P55878, P55879, Q0VGT2, Q15915, Q17308, Q5IS56, Q61467, Q61602, Q62520, Q62521, Q6DJQ6, Q6GR30, Q6XP49, Q6ZN18, Q7JNM3, Q7K0S9, Q7SXV2, Q7TQ40, Q8JJC0, Q8K1M4, Q8N9L1, Q8NBF1, Q8NEA6, Q8SV95, Q8VDL9

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
GLIS1	“up-regulates quantity by expression”	WNT5A	“transcriptional regulation”
AP1	“up-regulates quantity by expression”	GLIS1	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

131 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	113
Likely benign	4
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

3665 predictions. Top by Δscore:

Variant	Effect	Δscore
1:53509114:GCTCA:G	donor_loss	1.0000
1:53509115:CTCAC:C	donor_loss	1.0000
1:53509116:TCAC:T	donor_loss	1.0000
1:53509117:CACC:C	donor_loss	1.0000
1:53509118:A:T	donor_loss	1.0000
1:53509119:C:CG	donor_loss	1.0000
1:53520630:GTAC:G	donor_loss	1.0000
1:53520631:TA:T	donor_loss	1.0000
1:53520632:A:AC	donor_gain	1.0000
1:53520632:A:AG	donor_loss	1.0000
1:53520633:C:CC	donor_gain	1.0000
1:53520633:C:CT	donor_loss	1.0000
1:53520762:TGCAG:T	acceptor_gain	1.0000
1:53520763:GCAG:G	acceptor_gain	1.0000
1:53520763:GCAGC:G	acceptor_loss	1.0000
1:53520764:CAG:C	acceptor_gain	1.0000
1:53520764:CAGC:C	acceptor_gain	1.0000
1:53520764:CAGCT:C	acceptor_loss	1.0000
1:53520765:AG:A	acceptor_gain	1.0000
1:53520765:AGCTG:A	acceptor_loss	1.0000
1:53520766:GC:G	acceptor_loss	1.0000
1:53520767:C:CC	acceptor_gain	1.0000
1:53520767:CTG:C	acceptor_loss	1.0000
1:53520768:T:G	acceptor_loss	1.0000
1:53520775:C:CT	acceptor_gain	1.0000
1:53520776:A:T	acceptor_gain	1.0000
1:53520779:C:CT	acceptor_gain	1.0000
1:53529785:GCCTA:G	donor_loss	1.0000
1:53529786:CCTAC:C	donor_loss	1.0000
1:53529787:CTACC:C	donor_loss	1.0000

AlphaMissense

5116 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:53524874:C:G	C324S	1.000
1:53524875:A:G	C324R	1.000
1:53524875:A:T	C324S	1.000
1:53529800:G:C	H316Q	1.000
1:53529800:G:T	H316Q	1.000
1:53529812:G:C	H312Q	1.000
1:53529812:G:T	H312Q	1.000
1:53529814:G:C	H312D	1.000
1:53529822:C:G	R309P	1.000
1:53529823:G:T	R309S	1.000
1:53529839:G:C	F303L	1.000
1:53529839:G:T	F303L	1.000
1:53529840:A:C	F303C	1.000
1:53529840:A:G	F303S	1.000
1:53529841:A:G	F303L	1.000
1:53529841:A:T	F303I	1.000
1:53529852:C:G	C299S	1.000
1:53529853:A:G	C299R	1.000
1:53529853:A:T	C299S	1.000
1:53529866:G:C	C294W	1.000
1:53529867:C:G	C294S	1.000
1:53529867:C:T	C294Y	1.000
1:53529868:A:G	C294R	1.000
1:53529868:A:T	C294S	1.000
1:53529890:G:C	H286Q	1.000
1:53529890:G:T	H286Q	1.000
1:53529892:G:C	H286D	1.000
1:53529896:C:A	R284S	1.000
1:53529896:C:G	R284S	1.000
1:53529897:C:G	R284T	1.000

dbSNP variants (sampled 300 via entrez): RS1000002087 (1:53736533 C>T), RS1000005714 (1:53569852 A>G,T), RS1000033342 (1:53736308 AC>A), RS1000037210 (1:53718342 C>G,T), RS1000065933 (1:53605408 G>T), RS1000079481 (1:53562968 G>A,T), RS1000092585 (1:53694359 T>C), RS1000097834 (1:53695112 C>A,T), RS1000105598 (1:53554984 T>G), RS1000108928 (1:53518523 A>C), RS1000116772 (1:53688470 T>C), RS1000136036 (1:53536075 T>C), RS1000136386 (1:53524561 G>T), RS1000140958 (1:53575174 A>G), RS1000148337 (1:53695957 C>T)

Disease associations

OMIM: gene MIM:610378 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
glaucoma	Limited	Autosomal recessive

Mondo (1): glaucoma (MONDO:0005041)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST000635_11	Response to statin therapy	8.000000e-06
GCST002132_1	Non-substance related behavioral disinhibition	2.000000e-06
GCST002135_3	Nicotine use	5.000000e-06
GCST003094_7	Mitral valve prolapse	1.000000e-07
GCST003996_5	Monobrow	2.000000e-45
GCST003999_8	Nose size	3.000000e-09
GCST004069_8	Cerebrospinal fluid AB1-42 levels	2.000000e-08
GCST005235_4	Hand grip strength	5.000000e-12
GCST005748_1	Digit length ratio (right hand)	2.000000e-08
GCST005749_10	Digit length ratio (left hand)	8.000000e-09
GCST005749_11	Digit length ratio (left hand)	5.000000e-10
GCST005750_1	Digit length ratio	2.000000e-11
GCST005830_99	Hand grip strength	4.000000e-12
GCST010002_385	Refractive error	7.000000e-13
GCST90011768_11	Glaucoma (primary open-angle)	8.000000e-07
GCST90011770_27	Glaucoma (primary open-angle)	6.000000e-08

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0005432	non-substance related disinhibited behaviour
EFO:0005430	nicotine use
EFO:0007906	synophrys measurement
EFO:0004670	beta-amyloid 1-42 measurement
EFO:0006941	grip strength measurement
EFO:0004841	digit length ratio

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D005901	Glaucoma	C11.525.381

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

27 total (human), top 27 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases methylation	2
Smoke	increases expression	2
Aflatoxin B1	affects methylation, decreases expression	2
TAK-243	increases sumoylation	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	decreases methylation	1
terbufos	increases methylation	1
arsenite	affects binding, decreases reaction	1
sodium arsenite	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
Resveratrol	affects cotreatment, decreases expression	1
Atrazine	increases expression	1
Fonofos	increases methylation	1
Formaldehyde	increases expression	1
Methapyrilene	increases methylation	1
Niclosamide	increases expression	1
Parathion	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Tobacco Smoke Pollution	decreases methylation	1
Valproic Acid	increases methylation	1
Asbestos, Crocidolite	affects expression	1
Antirheumatic Agents	increases expression	1
Cadmium Chloride	decreases expression	1
Lactic Acid	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_HC76	HEK293 eGFP-GLIS1	Transformed cell line	Female

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00061503	PHASE4	COMPLETED	Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension
NCT00143208	PHASE4	COMPLETED	Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
NCT00224289	PHASE4	COMPLETED	Effect of Age on Latanoprost 0.005% in Patients With Glaucoma
NCT00273221	PHASE4	UNKNOWN	Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled Trial
NCT00329095	PHASE4	COMPLETED	An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
NCT00345046	PHASE4	COMPLETED	A Comparison of Three Different Formulations of Prednisolone Acetate 1%
NCT00346489	PHASE4	COMPLETED	Outcomes of Intraoperative 5-Fluorouracil Versus Mitomycin C
NCT00347035	PHASE4	TERMINATED	INFLUENCE OF TOPICAL INDOMETHACIN ON HYPOTHENSIVE EFFECT OF BRIMONIDINE
NCT00347802	PHASE4	COMPLETED	Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%
NCT00347841	PHASE4	COMPLETED	Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
NCT00348023	PHASE4	COMPLETED	Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension
NCT00348062	PHASE4	COMPLETED	A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension
NCT00348400	PHASE4	COMPLETED	Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost
NCT00351429	PHASE4	COMPLETED	Study of PGA Suture in Ophthalmology
NCT00376974	PHASE4	UNKNOWN	The Effect of Education on Patient Compliance
NCT00379834	PHASE4	COMPLETED	12-Month Stability of Diurnal IOP Control on Cosopt
NCT00382226	PHASE4	COMPLETED	IOP-Lowering Efficacy of Brinzolamide 1.0% Added to Travoprost 0.004%/Timolol 0.5% Fixed Combination as Adjunctive Therapy
NCT00404729	PHASE4	COMPLETED	Neural Conduction Along the Visual Pathways After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases
NCT00440011	PHASE4	COMPLETED	Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
NCT00440141	PHASE4	COMPLETED	Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%
NCT00442312	PHASE4	UNKNOWN	Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy
NCT00444184	PHASE4	COMPLETED	24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost
NCT00444665	PHASE4	COMPLETED	Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
NCT00449098	PHASE4	UNKNOWN	Ologen (OculusGen)-Glaucoma MMC Control Trial in India
NCT00466479	PHASE4	COMPLETED	Brimonidine vs ALTP in Progressing Human Glaucoma
NCT00468429	PHASE4	UNKNOWN	Subconjunctival Bevacizumab to Prevent Bleb Failure After Glaucoma Filtration Surgery
NCT00468988	PHASE4	COMPLETED	Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers
NCT00471380	PHASE4	COMPLETED	A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension
NCT00485238	PHASE4	UNKNOWN	ALPI vs Medical Therapy Effects on Optic Nerve Structure & Function
NCT00486486	PHASE4	COMPLETED	24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination
NCT00519753	PHASE4	COMPLETED	Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav
NCT00541242	PHASE4	COMPLETED	Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension
NCT00557232	PHASE4	COMPLETED	Intraocular Bevacizumab (Avastin) for Rubeosis Iridis
NCT00597181	PHASE4	TERMINATED	A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy
NCT00607685	PHASE4	COMPLETED	5FU vs 5FU With Viscoelastic Formulation for the Prevention of Scarring Post-trabeculectomy
NCT00626067	PHASE4	COMPLETED	Study of Patient Use and Perception of the Travatan Dosing Aid
NCT00666237	PHASE4	COMPLETED	Primary Tube Versus Trabeculectomy Study
NCT00698438	PHASE4	COMPLETED	Comparison Of Trabeculectomy Versus The Ex-PRESS Miniature Glaucoma Device In The Same Patient: A Prospective Randomized Study
NCT00705757	PHASE4	COMPLETED	The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye
NCT00708422	PHASE4	COMPLETED	Effects of Travatan Z and Xalatan on Ocular Surface Health